PUMA BIOTECHNOLOGY, INC.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2022 | $97.4M | $7.1M | $63.9M |
| Jun 2022 | $97.7M | $19.7M | $52.8M |
| Sep 2022 | $98.0M | $22.2M | $78.0M |
| Dec 2022 | $98.3M | $21.6M | $76.2M |
| Mar 2023 | $98.6M | $25.8M | $61.4M |
| Jun 2023 | $87.6M | $30.4M | $60.0M |
| Sep 2023 | $76.6M | $38.7M | $81.8M |
| Dec 2023 | $65.7M | $53.4M | $84.6M |
| Mar 2024 | $54.7M | $51.0M | $76.8M |
| Jun 2024 | $43.7M | $48.5M | $67.1M |
| Sep 2024 | $32.7M | $71.1M | $67.3M |
| Dec 2024 | $21.7M | $92.1M | $69.2M |
| Mar 2025 | $10.6M | $97.1M | $63.0M |
| Jun 2025 | $10.9M | $104.7M | $54.7M |
| Sep 2025 | $0 | $115.3M | $53.5M |
| Dec 2025 | $0 | $130.3M | $29.6M |
| Mar 2026 | $0 | $128.4M | $36.2M |
| Jun 2026 | $0 | $138.5M | $36.5M |